Momeson - Mometasone Furoate (Inhalation Capsule) | VetSafeCare.Com

Brand

Momeson

Mometasone Furoate (Inhalation Capsule) — Incepta Pharmaceuticals Ltd.
220mcg / inhalation capsule

Alternatives

1

Routes

INH

Presentations

1

Generic profile Browse alternatives View combinations

Presentations

Inhalation Capsule · 220mcg / inhalation capsule

1 inhaler

৳10

Dose rules

No structured dose rules are linked to this brand yet.

Dose reference

Human

Recommended Dosages in Patients 4 Years of Age and Older.Previous Therapy: Patients ≥ 12 years who received bronchodilators alone  Recommended Starting Dose: 220 µg once daily in the evening Highest Recommended Daily: 220 µg twice daily or as 440 µg once daily Previous Therapy: Patients ≥ 12 years who received inhaled corticosteroids Recommended Starting Dose: 220 µg once daily Highest Recommended Daily: 440 µg once daily or 440 µg twice daily. Previous Therapy: Patients ≥ 12 years who received oral corticosteroids Recommended Starting Dose: 4400 µg once daily Highest Recommended Daily: 440 µg once daily or 440 µg twice daily.

Clinical notes

Applications:

N/A

Indication Notes:
Mometasone Furoate is indicated for the maintenance treatment of asthma as prophylactic therapy in patients 4 years of age and older. It is not indicated for the relief of acute bronchospasm. It is not indicated in children less than 4 years of age.
Avoid In:

N/A

Contraindication Notes:
Hypersensitivity to any of the ingredients of this preparation contraindicates its use. Mometasone Furoate therapy is contraindicated in the primary treatment of status asthmaticus or other acute episodes of asthma where intensive measures are required.
Mometasone is a corticosteroid demonstrating anti-inflammatory properties. The precise mechanism of corticosteroids action on allergic rhinitis is not known. Corticosteroids have been shown to have a wide range of effects on multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, and lymphocytes) and mediators (e.g., histamine, eicosanoids, leukotrienes, and cytokines) involved in inflammation.
Ketoconazole, a strong inhibitor of cytochrome P4503A4 may increase plasma levels of Mometasone Furoate during concomitant dosing.
Generally side effects are mild like headache, viral infection, sore throat, nosebleeds and coughing. Systemic and local corticosteroid use may result few side effects like candida infection, immunosuppression, hypercorticism, adrenal suppression, growth effects, glaucoma and cataracts.
There are no data available on the effects of acute or chronic over dosage with Mometasone Furoate. Because of low systemic bioavailability and an absence of acute drug-related systemic findings in clinical studies, overdose is unlikely to require any therapy other than observation.
Pregnancy: There are no adequate and well-controlled studies in pregnant women. Mometasone Furoate, like other corticosteroids should be used during pregnancy only if the potential benefits justify the potential risk to the fetus.Lactation: It is not known if Mometasone Furoate is excreted in human milk. Since other corticosteroids are excreted in human milk, caution should be used when Mometasone Furoate is administered to nursing women.
Use with caution in active or inactive tuberculosis infection, herpes simplex virus infection of the eye, untreated infections affecting the body as a whole etc.